This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Varian Medical's (VAR) ProBeam Compact Picked by Biopolis
by Zacks Equity Research
The development is likely to boost Varian Medical's (VAR) Proton business that declined 12% year over year in the last reported quarter.
ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio
by Zacks Equity Research
ResMed's (RMD) AirFit N30i with a top-of-head connection keeps tubing out of the wearers' way, thus letting them conveniently move and sleep in any position.
CVS Health's PBM Pharmacy Platform to Ride on Walmart Deal
by Zacks Equity Research
Per the terms of the deal between CVS Health (CVS) and Walmart, the latter will continue to take part in the CVS Caremark PBM commercial and Managed Medicaid retail pharmacy networks.
Quest Diagnostics' Core Diagnostics Strong Amid Several Woes
by Zacks Equity Research
Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.
Neogen Gains on Strong Genomic Arm Amid Stiff Competition
by Zacks Equity Research
Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.
The Zacks Analyst Blog Highlights: Veeva, Attunity, Microsoft, Cloudera and Facebook
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Veeva, Attunity, Microsoft, Cloudera and Facebook
Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.
Baxter (BAX) Gains From Sharesource's Global Success Rates
by Zacks Equity Research
Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.
Here's Why Investors Should Hold AngioDynamics (ANGO) Now
by Zacks Equity Research
AngioDynamics' (ANGO) flagship NanoKnife System is currently witnessing robust demand.
Cerner Picked by Remi Vista for Behavioral Health Technology
by Zacks Equity Research
Apart from Cerner Integrated, Cerner's (CERN) revenue cycle solutions will help Remi Vista's financial operations.
3 Cloud Stocks to Buy Right Now
by Ryan McQueeney
In a matter of just a few years, "the Cloud" has evolved from a budding new tech feature to one of the main factors driving growth in the technology sector. With this in mind, we've highlighted three stocks that are showing strong cloud-related activity. Check out these three cloud stocks to buy right now!
Here's Why Investors Should Retain athenahealth (ATHN) Stock
by Zacks Equity Research
athenahealth (ATHN) gains from a broad product portfolio. However, it faces stiff competition in the MedTech space.
Henry Schein Animal Health Spin-Off Approaches, Cost Mounts
by Zacks Equity Research
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Allscripts Selected by Premier for Connected Health Platform
by Zacks Equity Research
Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.
Veeva Systems (VEEV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $101.66, moving +0.26% from the previous trading session.
Why You Should Consider Buying Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.
Here's Why You Should Invest in OPKO Health (OPK) Right Now
by Zacks Equity Research
OPKO Health's (OPK) flagship RAYALDEE lends it a competitive edge in the MedTech space.
Here's Why Investors Should Hold Patterson Companies Stock
by Zacks Equity Research
Patterson Companies (PDCO) gains from solid foothold in theAnimals Health business. However, the company is facing headwinds in the Dental segment.
Oracle at NRF 2019: One Door Tie-Up, Growing Retail Clientele
by Zacks Equity Research
Oracle (ORCL) is raising the bar in digital commerce with new collaborations. Moreover, Oracle Retail services are witnessing traction.
QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands
by Zacks Equity Research
QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.
Here's Why Investors Should Hold McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) gains traction from a solid foothold in the pharmaceutical and medical supplies distribution market. However, the company is grappled with regulatory constraints in Canada.
Oracle Ups Ante in Digital Commerce with New Retail Services
by Zacks Equity Research
Oracle (ORCL) ramps up Retail Omnichannel product suite at NRF 2019, in a bid to enable retailers to provide customers with improved shopping experience.
IBM to Reportedly Buy T-Systems' Mainframe Business Unit
by Zacks Equity Research
IBM (IBM) is reportedly buying mainframe service business of T-Systems amid cash crunch to capitalize on the growth prospects in the domain.
Cerner & Christiana Care Unite to Offer Bariatric Services
by Zacks Equity Research
Cerner (CERN) likely to gain from increased obesity rates in the United States.